Clinical Management

Patients in the medical arm generally described gradual, modest, or no improvement. Some medical-arm patients reported little or no change in symptoms or quality of life. The study did not establish new predictive markers and called for future risk stratification and biomarker validation. Daily sinus rinses made it difficult for patients to know whether improvements came from oral medication or rinsing. GLP-1 receptor agonists, rivaroxaban, SGLT2 inhibitors, antiplatelet agents, statins, and anti-inflammatory drugs are proposed for future study rather than established treatment in this overlap. Side effects in the medical arm were mostly gastrointestinal and clarithromycin was viewed as generally well tolerated. The article supports close monitoring immediately after COPD exacerbations, especially in patients with cardiovascular comorbidities. Suggested monitoring parameters included oxygen saturation, blood gases, ECG changes, and cardiac biomarkers. Care strategies should manage respiratory and cardiovascular risks together. The study recommends adding ASCVD burden to ICU sepsis risk stratification. Concurrent sepsis and ASCVD management is described as requiring multidisciplina…